Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer

Summary

This phase II trial studies how well sapanisertib works in treating patients with lung cancer that is stage IV or has come back (recurrent) and has a mutation in the NFE2L2, KEAP-1, or KRAS gene. Damage to these genes may cause the cancer to grow. Sapanisertib may stop this from happening by blocking enzymes.

Timeline

Start

2016-10-06

Primary completion

2020-12-28

Completion

2020-12-28

Drugs

Indications